Greenwich LifeSciences (GLSI) Accounts Payables (2019 - 2025)
Greenwich LifeSciences (GLSI) posted Accounts Payables of $4.9 million for Q4 2025, up 339.58% on a QoQ basis from $1.1 million in Q3 2025, and up 73.91% year-over-year from $2.8 million in Q4 2024.
Greenwich LifeSciences (GLSI) Accounts Payables (2019 - 2025) Analysis & Trends
Greenwich LifeSciences' Accounts Payables history runs 7 years deep, the most recent figure standing at $4.9 million for Q4 2025.
- Quarterly Accounts Payables rose 73.91% year-over-year to $4.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.9 million (up 73.91% YoY) and the FY2025 annual result came in at $4.9 million, up 73.91% from the prior year.
- Accounts Payables was $4.9 million for Q4 2025 at Greenwich LifeSciences, up from $1.1 million in the prior quarter.
- Across five years, Accounts Payables topped out at $4.9 million in Q4 2025 and bottomed at $220845.0 in Q4 2021.
- A 5-year average of $859861.3 and a median of $323522.5 in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2021 — Accounts Payables slumped 68.94% — and 2024, when it jumped 1169.19%.
- Greenwich LifeSciences' Accounts Payables stood at $220845.0 in 2021, then changed by 0.0% to $220845.0 in 2022, then changed by 0.0% to $220845.0 in 2023, then soared by 1169.19% to $2.8 million in 2024, then surged by 73.91% to $4.9 million in 2025.
- Business Quant data shows GLSI's Accounts Payables at $4.9 million in Q4 2025, $1.1 million in Q3 2025, and $1.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | Greenwich LifeSciences | 178.53 Mn | 178.53 Mn | - | 4.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.87 Mn |
| Sep 30, 2025 | 1.11 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.05 Mn |
| Dec 31, 2024 | 2.80 Mn |
| Sep 30, 2024 | 774,759.00 |
| Jun 30, 2024 | 1.34 Mn |
| Mar 31, 2024 | 346,582.00 |
| Dec 31, 2023 | 220,845.00 |
| Sep 30, 2023 | 230,902.00 |
| Jun 30, 2023 | 300,463.00 |
| Mar 31, 2023 | 220,845.00 |
| Dec 31, 2022 | 220,845.00 |
| Sep 30, 2022 | 220,845.00 |
| Jun 30, 2022 | 220,845.00 |
| Mar 31, 2022 | 220,845.00 |
| Dec 31, 2021 | 220,845.00 |
| Sep 30, 2021 | 295,845.00 |
| Jun 30, 2021 | 627,577.00 |
| Mar 31, 2021 | 609,274.00 |